奥法妥珠单抗。
Ofatumumab.
机构信息
Harvard University, Department of Health Policy and Management, School of Public Health, Boston, MA 02115, USA.
出版信息
MAbs. 2009 Jul-Aug;1(4):326-31. doi: 10.4161/mabs.1.4.8895. Epub 2009 Jul 1.
Abstract
Ofatumumab is an anti-CD20 IgG1kappa human monoclonal antibody that is being considered by the US Food and Drug Administration and the European Medicines Agency for marketing approval as a treatment for chronic lymphocytic leukemia. The mAb is also being studied as a treatment for lymphoma, rheumatoid arthritis and multiple sclerosis. The candidate targets the same antigen as rituximab, but ofatumumab binds a novel, membrane-proximal epitope, and dissociates from its target at a slower rate compared to rituximab. Ofatumumab might be approved in the US by August 2009.
摘要
奥法妥木单抗是一种抗 CD20 IgG1kappa 人源单克隆抗体，目前正由美国食品药品监督管理局和欧洲药品管理局考虑批准上市，用于治疗慢性淋巴细胞白血病。该药还在研究用于治疗淋巴瘤、类风湿关节炎和多发性硬化症。该候选药物的靶点与利妥昔单抗相同，但奥法妥木单抗结合的是一个新的、靠近细胞膜的表位，与利妥昔单抗相比，其从靶点解离的速度更慢。奥法妥木单抗有望于 2009 年 8 月在美国获得批准。
相似文献
1
Ofatumumab.奥法妥珠单抗。
MAbs. 2009 Jul-Aug;1(4):326-31. doi: 10.4161/mabs.1.4.8895. Epub 2009 Jul 1.
2
Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis.奥法木单抗在慢性淋巴细胞白血病、滤泡性淋巴瘤和类风湿关节炎患者中的群体药代动力学。
J Clin Pharmacol. 2014 Jul;54(7):818-27. doi: 10.1002/jcph.268. Epub 2014 Jan 28.
3
Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia.奥法妥木单抗：一种用于 B 细胞慢性淋巴细胞白血病的新型 CD20 单克隆抗体疗法。
Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):361-8. doi: 10.3816/CLML.2010.n.069.
4
The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use.欧洲药品管理局对奥法妥珠单抗（Arzerra®）治疗氟达拉滨和阿仑单抗难治性慢性淋巴细胞白血病的审评：人用药品委员会对欧洲药品管理局评估的科学总结。
Oncologist. 2010;15(12):1335-43. doi: 10.1634/theoncologist.2010-0255. Epub 2010 Dec 14.
5
Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.奥法妥木单抗（一种人源抗 CD20 抗体）治疗复发或难治性慢性淋巴细胞白血病和小淋巴细胞淋巴瘤的日本患者的 I 期研究。
Jpn J Clin Oncol. 2013 May;43(5):466-75. doi: 10.1093/jjco/hyt022. Epub 2013 Feb 28.
6
rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.rILYd4，一种人源 CD59 抑制剂，增强奥法木单抗对利妥昔单抗耐药 B 细胞淋巴瘤细胞和慢性淋巴细胞白血病的补体依赖性细胞毒性。
Clin Cancer Res. 2011 Nov 1;17(21):6702-11. doi: 10.1158/1078-0432.CCR-11-0647. Epub 2011 Sep 14.
7
Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.奥法妥木单抗治疗新诊断和复发/难治性慢性淋巴细胞白血病。
Expert Rev Anticancer Ther. 2011 Feb;11(2):151-60. doi: 10.1586/era.10.223.
8
Ofatumumab for the treatment of chronic lymphocytic leukemia.奥法木单抗用于治疗慢性淋巴细胞白血病。
Expert Rev Hematol. 2015 Jun;8(3):265-72. doi: 10.1586/17474086.2015.1037736. Epub 2015 Apr 16.
9
Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.奥法妥珠单抗，一种新型抗 CD20 单克隆抗体，用于治疗 B 细胞恶性肿瘤。
J Clin Oncol. 2010 Jul 20;28(21):3525-30. doi: 10.1200/JCO.2010.27.9836. Epub 2010 May 10.
10
Ofatumumab for relapsing forms of multiple sclerosis.奥法妥木单抗治疗多发性硬化的复发型。
Drugs Today (Barc). 2022 Jan;58(1):9-21. doi: 10.1358/dot.2022.58.1.3353168.
引用本文的文献
1
Case Report: Clinical features and management of anti-mGluR1 encephalitis: case illustration and review of the literature.病例报告：抗代谢型谷氨酸受体1脑炎的临床特征与治疗：病例说明及文献综述
Front Integr Neurosci. 2025 Jul 23;19:1580767. doi: 10.3389/fnint.2025.1580767. eCollection 2025.
2
Anti-CD20 therapy in lupus nephritis: A revisit.狼疮性肾炎中的抗CD20疗法：再探讨
Rheumatol Immunol Res. 2025 Jul 1;6(2):66-69. doi: 10.1515/rir-2025-0009. eCollection 2025 Jun.
3
Newer B-cell and plasma-cell targeted treatments for rituximab-resistant patients with membranous nephropathy.针对利妥昔单抗耐药的膜性肾病患者的新型B细胞和浆细胞靶向治疗方法。
Clin Kidney J. 2025 Mar 21;18(5):sfaf088. doi: 10.1093/ckj/sfaf088. eCollection 2025 May.
4
CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives.用于系统性红斑狼疮的嵌合抗原受体T细胞疗法：现状与未来展望
Front Immunol. 2024 Dec 19;15:1476859. doi: 10.3389/fimmu.2024.1476859. eCollection 2024.
5
Case report: The case report of ofatumumab, a fully human anti-CD20 monoclonal antibody, in the treatment of KLHL11 encephalitis.病例报告：奥法木单抗，一种完全人源抗 CD20 单克隆抗体，治疗 KLHL11 脑炎的病例报告。
Front Immunol. 2024 Nov 7;15:1456840. doi: 10.3389/fimmu.2024.1456840. eCollection 2024.
6
Cancer immunotherapies: A hope for the uncurable?癌症免疫疗法：治愈绝症的希望？
Front Mol Med. 2023 Feb 17;3:1140977. doi: 10.3389/fmmed.2023.1140977. eCollection 2023.
7
A Comprehensive Review on the Efficacy of Anti-CD20 Therapies in Pemphigus Treatment.抗CD20疗法在天疱疮治疗中疗效的综合综述
Cureus. 2024 Apr 23;16(4):e58834. doi: 10.7759/cureus.58834. eCollection 2024 Apr.
8
Myasthenia gravis: the changing treatment landscape in the era of molecular therapies.重症肌无力：分子治疗时代不断变化的治疗前景。
Nat Rev Neurol. 2024 Feb;20(2):84-98. doi: 10.1038/s41582-023-00916-w. Epub 2024 Jan 8.
9
The MR1/MAIT cell axis in CNS diseases.中枢神经系统疾病中的MR1/黏膜相关恒定T细胞轴
Brain Behav Immun. 2024 Feb;116:321-328. doi: 10.1016/j.bbi.2023.12.029. Epub 2023 Dec 27.
10
Methods for Engineering Binders to Multi-Pass Membrane Proteins.将结合剂工程化应用于多次跨膜蛋白的方法。
Bioengineering (Basel). 2023 Nov 24;10(12):1351. doi: 10.3390/bioengineering10121351.
本文引用的文献
1
Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis.利妥昔单抗或奥法木单抗致敏的B淋巴细胞上的补体激活在细胞裂解前会导致膜结构发生显著变化。
J Immunol. 2008 Jul 1;181(1):822-32. doi: 10.4049/jimmunol.181.1.822.
2
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.新型全人源抗CD20单克隆抗体奥法木单抗在复发或难治性滤泡性淋巴瘤中的首次临床应用：一项1/2期试验的结果
Blood. 2008 Jun 15;111(12):5486-95. doi: 10.1182/blood-2007-10-117671. Epub 2008 Apr 4.
3
Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody.治疗性人抗CD20抗体体内持续活性的剂量需求估算
Br J Haematol. 2008 Feb;140(3):303-12. doi: 10.1111/j.1365-2141.2007.06916.x. Epub 2007 Nov 27.
4
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.全人源单克隆抗CD20抗体奥法木单抗在复发或难治性B细胞慢性淋巴细胞白血病患者中的安全性和有效性：一项1-2期研究。
Blood. 2008 Feb 1;111(3):1094-100. doi: 10.1182/blood-2007-09-111781. Epub 2007 Nov 14.
5
Role of B cells in pathogenesis of multiple sclerosis.B细胞在多发性硬化症发病机制中的作用。
Int Rev Neurobiol. 2007;79:13-42. doi: 10.1016/S0074-7742(07)79002-5.
6
On the occurrence of a factor in human serum activating the specific agglutintion of sheep blood corpuscles. 1939.关于人血清中一种能激活绵羊血细胞特异性凝集的因子的发现。1939年。
APMIS. 2007 May;115(5):422-38; discussion 439. doi: 10.1111/j.1600-0463.2007.apm_682a.x.
7
The non-Hodgkin lymphomas: a review of the epidemiologic literature.非霍奇金淋巴瘤：流行病学文献综述
Int J Cancer. 2007;120 Suppl 12:1-39. doi: 10.1002/ijc.22719.
8
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.人CD20单克隆抗体的生物学活性与CD20上独特的表位相关。
J Immunol. 2006 Jul 1;177(1):362-71. doi: 10.4049/jimmunol.177.1.362.
9
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.具有针对非霍奇金淋巴瘤强大细胞溶解活性的新型人CD20单克隆抗体的特性分析。
Blood. 2004 Sep 15;104(6):1793-800. doi: 10.1182/blood-2004-01-0039. Epub 2004 Jun 1.
10
Anti-CD20-based therapy of B cell lymphoma: state of the art.基于抗CD20的B细胞淋巴瘤治疗：当前进展
Leukemia. 2002 Oct;16(10):2004-15. doi: 10.1038/sj.leu.2402639.
Zotero 插件